(Nasdaq: SEEL) 300 Park Ave., 12th Fl New York, NY 10022 (646) 293-2136 [email protected]:/seelostherapeutics.com/twitter.com/see “The modification.com of this agreement for the development of SLS-002 allows us to: continue our plans, conduct a proof of concept study to evaluate the safety and tolerability, and efficacy of SLS-002, as well as research on the validation of sheehan Suicidality Tracking Scale in this population.